Evidence map›Paper›PMID 33422981›Full record

ArticleEuropean journal of medicinal chemistry2021

Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition.

Zafer Sahin, Sevde Nur Biltekin, Leyla Yurttas, Barkin Berk, Yağmur Özhan, Hande Sipahi, Zhan-Guo Gao, Kenneth A Jacobson, Şeref Demirayak

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Zafer SahinIstanbul Medipol University, School of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul, Turkey. Electronic address: zsahin@medipol.edu.tr.
Sevde Nur BiltekinIstanbul Medipol University, School of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul, Turkey.
Leyla YurttasAnadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Eskisehir, Turkey.
Barkin BerkIstanbul Medipol University, School of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul, Turkey.
Yağmur ÖzhanYeditepe University, Faculty of Pharmacy, Department of Toxicology, Istanbul, Turkey.
Hande SipahiYeditepe University, Faculty of Pharmacy, Department of Toxicology, Istanbul, Turkey.
Zhan-Guo GaoMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA.
Şeref DemirayakIstanbul Medipol University, School of Pharmacy, Department of Pharmaceutical Chemistry, Istanbul, Turkey.
Istanbul Medipol University · TRNational Institutes of Health · USYeditepe University · TRAnadolu University · TR

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Intramural NIH HHS ZIA DK031117
6 · The paper itself

Abstract

Thiouracil and thiocytosine are important heterocyclic pharmacophores having pharmacological diversity. Antitumor and antiviral activity is commonly associated with thiouracil and thiocytosine derivatives, which are well known fragments for adenosine receptor affinity with many associated pharmacological properties. In this respect, 33 novel compounds have been synthesized in two groups: 24 thiouracil derivatives (4a-x) and 9 thiocytosine derivatives (5a-i). Antitumor activity of all the compounds was determined in the U87 MG glioblastoma cell line. Compound 5e showed an anti-proliferative IC

Indexed as

Antineoplastic AgentsBinding SitesCell ProliferationCells, CulturedCell SurvivalCyclic Nucleotide Phosphodiesterases, Type 4CytosineDose-Response Relationship, DrugDrug Screening Assays, AntitumorGlioblastomaHumansMolecular StructurePhosphodiesterase 4 InhibitorsReceptors, Purinergic P1Structure-Activity RelationshipThiouracilAntineoplastic AgentsCyclic Nucleotide Phosphodiesterases, Type 4CytosinePDE4A protein, humanPhosphodiesterase 4 InhibitorsReceptors, Purinergic P1ThiouracilAdenosineAntitumorHEK293MCF7PDEPhosphosdiesteraseThiocytosineThiouracilU87

Identifiers

PMID33422981
PMCPMC7880896
OpenAlexW3115872106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.